Skip to main content
APRE
NASDAQ Life Sciences

Wiseek Filing Insight

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
4
Price
$0.807
Mkt Cap
$10.141M
52W Low
$0.548
52W High
$2.22
Market data snapshot near publication time

check_boxKey Events

  • No key events were highlighted for this filing.

auto_awesomeAnalysis

No analysis available.

At the time of this filing, APRE was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1M. The 52-week trading range was $0.55 to $2.22. This filing was assessed with an importance score of 4 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed APRE - Latest Insights

APRE
Apr 29, 2026, 5:15 PM EDT
Filing Type: 424B3
Importance Score:
9
Aprea Therapeutics Finalizes Resale of 74.3M Shares, Securing $25.4M in Warrant Exercise Proceeds Amidst Massive Dilution
Sentiment: Negative
View Wiseek Article
APRE
Apr 22, 2026, 5:01 PM EDT
Filing Type: S-3
Importance Score:
9
Aprea Therapeutics Registers Resale of 74.3M Shares and Warrants, Signaling Massive Potential Dilution
Sentiment: Negative
View Wiseek Article
APRE
Apr 20, 2026, 6:30 AM EDT
Filing Type: PRE 14A
Importance Score:
8
Aprea Therapeutics Seeks Shareholder Approval for Reverse Stock Split to Maintain Nasdaq Listing
Sentiment: Negative
View Wiseek Article
APRE
Apr 01, 2026, 4:15 PM EDT
Filing Type: 4
Importance Score:
7
CFO Buys $25K in Warrants as Part of Recent Private Placement
Sentiment: Positive
View Wiseek Article
APRE
Apr 01, 2026, 4:15 PM EDT
Filing Type: 4
Importance Score:
9
Director Richard Peters Invests $100K in Aprea Therapeutics' Critical Private Placement
Sentiment: Positive
View Wiseek Article
APRE
Mar 30, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
10
Aprea Therapeutics Secures $30M Oversubscribed Private Placement, Extends Runway, and Reports Positive Clinical Data
Sentiment: Positive
View Wiseek Article
APRE
Mar 30, 2026, 8:04 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Aprea Therapeutics Announces $30M Private Placement, Signaling Significant Dilution
Sentiment: Negative
View Wiseek Article
APRE
Mar 19, 2026, 5:16 PM EDT
Filing Type: 424B3
Importance Score:
9
Aprea Therapeutics Registers 12.58 Million Shares for Resale, Representing 110% of Outstanding Stock; CEO and CFO Among Selling Stockholders
Sentiment: Negative
View Wiseek Article
APRE
Mar 16, 2026, 8:30 AM EDT
Filing Type: 10-K
Importance Score:
8
Aprea Therapeutics Reports Going Concern Doubt, Nasdaq Delisting Risk, and Positive Early Clinical Data for APR-1051
Sentiment: Negative
View Wiseek Article
APRE
Mar 16, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Aprea Therapeutics Reports Early Clinical Success for APR-1051 and Secures Critical $8.7M Financing
Sentiment: Neutral
View Wiseek Article